Chloroquine dose in renal failure

Discussion in 'Canada Pharmacy' started by jford, 04-Mar-2020.

  1. Baruchka New Member

    Chloroquine dose in renal failure


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Hydroxychloroquine syrup Plaquenil dosage for arthritis Hydroxychloroquine weigh Dangers of plaquenil in half

    To the Editor Drug Prescribing in Renal Failure by Bennett and colleagues 1 possibly contains a misprint. This excellent reference provides dosage recommendations for various drugs when prescribed for patients with differing degrees of renal dysfunction. The recommended dose of chloroquine for an adult is 300 mg once weekly and proguanil 200 mg once daily. 1. A 39‐year‐old Asian man with end stage renal failure of 18 months duration, secondary to congenital single kidney and hypertension, was hospitalised on his return from holiday to India. SARS causes renal failure in ~7% of patients. The pathology shows acute tubular necrosis, which appears to be a reflection of generalized multi-organ failure. In some cases rhabdomyolysis may have contributed as well. Renal failure correlates with a poor overall prognosis 92% mortality with renal failure versus 9% without.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Chloroquine dose in renal failure

    PLAQUENIL HYDROXYCHLOROQUINE SULFATE TABLETS, USP DESCRIPTION, The risk of antimalarials in patients with renal failure

  2. Chloroquine mechanism of action lysosome
  3. Initially by mouth using tablets. For Child 14–17 years body-weight 45 kg and above. 310 mg once weekly, alternatively by mouth using syrup 300 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.

    • CHLOROQUINE Drug BNF content published by NICE.
    • COVID-19 - EMCrit Project.
    • Chloroquine Oral Uses, Side Effects, Interactions, Pictures..

    The chloroquine dose should be reduced in patients with renal disease, as up to 70% of chloroquine is excreted unchanged in the urine. Chloroquine itself can cause reduced kidney function of up to 10% of patients, especially in those over 60 years of age. However, elderly patients are more likely to have age-related kidney problems, which may require caution and an adjustment in the dose for patients receiving chloroquine. Breastfeeding. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Background and objectives Hydroxychloroquine is widely used in patients with rheumatoid arthritis. However, large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking. We aimed to assess the long-term association of hydroxychloroquine use with the risk of developing CKD in this population.

     
  4. Feathery Moderator

    In some cases, they may not be available in every strength or form as the brand-name drug. Polymyositis PM - Muscular Dystrophy Association Hydroxychloroquine Side Effects, Dosage, Uses, and More Plaquenil and eye pain - HealthBoards
     
  5. Hydroxychloroquine Side-effects, uses, time to work Hydroxychloroquine is used to treat rheumatoid arthritis; discoid and systemic lupus erythematosus SLE. Over the long term hydroxychloroquine can reduce pain, swelling and joint stiffness. If you have lupus, it may also improve the rash. It may be as long as 12 weeks before you notice the benefits.

    Plaquenil Uses, Dosage & Side Effects -